MDT

96.46

-0.47%↓

A

146.44

-1.03%↓

VEEV

228.35

-1.98%↓

HQY

84.03

-0.27%↓

PHR.US

16.54

-3.44%↓

MDT

96.46

-0.47%↓

A

146.44

-1.03%↓

VEEV

228.35

-1.98%↓

HQY

84.03

-0.27%↓

PHR.US

16.54

-3.44%↓

MDT

96.46

-0.47%↓

A

146.44

-1.03%↓

VEEV

228.35

-1.98%↓

HQY

84.03

-0.27%↓

PHR.US

16.54

-3.44%↓

MDT

96.46

-0.47%↓

A

146.44

-1.03%↓

VEEV

228.35

-1.98%↓

HQY

84.03

-0.27%↓

PHR.US

16.54

-3.44%↓

MDT

96.46

-0.47%↓

A

146.44

-1.03%↓

VEEV

228.35

-1.98%↓

HQY

84.03

-0.27%↓

PHR.US

16.54

-3.44%↓

Search

MacroGenics Inc

Gesloten

SectorGezondheidszorg

1.74 -3.87

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

1.73

Max

1.8399999999999999

Belangrijke statistieken

By Trading Economics

Inkomsten

53M

17M

Verkoop

51M

73M

Winstmarge

23.095

Werknemers

341

EBITDA

55M

22M

Aanbevelingen

By TipRanks

Aanbevelingen

Neutraal

12 Maanden Prognose

+67.6% upside

Dividenden

By Dow Jones

Volgende Winsten

19 mrt 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

18M

109M

Vorige openingsprijs

5.61

Vorige sluitingsprijs

1.74

Nieuwssentiment

By Acuity

61%

39%

320 / 361 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Neutral Evidence

MacroGenics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

13 jan 2026, 19:05 UTC

Belangrijke Marktbewegers

Travere Therapeutics Shares Fall After FDA Extends Filspari Review

13 jan 2026, 23:41 UTC

Marktinformatie

Nikkei May Rise on Japan Election Hopes -- Market Talk

13 jan 2026, 23:41 UTC

Marktinformatie

Global Equities Roundup: Market Talk

13 jan 2026, 23:33 UTC

Marktinformatie

Gold Edges Higher, Supported by Ongoing Geopolitical Tensions -- Market Talk

13 jan 2026, 23:13 UTC

Acquisities, Fusies, Overnames

JD Logistics Plans to Withdraw Listing Status of Deppon Logistics From Shanghai Stock Exchange

13 jan 2026, 23:10 UTC

Acquisities, Fusies, Overnames

JD Logistics Makes Cash Offer to Buy Deppon Logistics Shares It Doesn't Already Own

13 jan 2026, 23:03 UTC

Marktinformatie

Woodside's Sales Revenue Likely Fell 13% in 4Q -- Market Talk

13 jan 2026, 21:50 UTC

Acquisities, Fusies, Overnames

Netflix Preparing to Make Warner Bid All-Cash -- WSJ

13 jan 2026, 21:50 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Basic Materials Roundup: Market Talk

13 jan 2026, 21:20 UTC

Acquisities, Fusies, Overnames

Versant Media: Katz Will Continue to Lead Day-To-Day Ops of FTN

13 jan 2026, 21:20 UTC

Acquisities, Fusies, Overnames

Versant Media: Transaction Strengthens Distribution Footprint and Expands Free-To-Watch Portfolio >VSNT

13 jan 2026, 21:20 UTC

Acquisities, Fusies, Overnames

Versant Media: Jonathan Katz, FTN's Founder, Has Joined VERSANT, Reporting to David Pietrycha >VSNT

13 jan 2026, 21:15 UTC

Acquisities, Fusies, Overnames

VERSANT Completes Acquisition Of Free TV Networks >VSNT

13 jan 2026, 21:08 UTC

Acquisities, Fusies, Overnames

Array Digital Infrastructure Declares Special Dividend of $10.25 >AD

13 jan 2026, 20:39 UTC

Marktinformatie

Silver Settles at Another New High -- Market Talk

13 jan 2026, 20:21 UTC

Marktinformatie

Oil Futures Extend Rally On Rising Iran Tensions -- Market Talk

13 jan 2026, 20:17 UTC

Marktinformatie

U.S. Natural Gas Edges Up on Coming Weather -- Market Talk

13 jan 2026, 19:08 UTC

Acquisities, Fusies, Overnames

Super Micro Computer Is an AI Winner. Sell the Stock Anyway, Goldman Sachs Says. -- Barrons.com

13 jan 2026, 19:03 UTC

Winsten

Double-Digit Earnings Growth Could Continue. It Still Might Not Satisfy Investors. -- Barrons.com

13 jan 2026, 18:50 UTC

Winsten

JPMorgan's Unusual Quarter Weighs on Shares. How Apple Plays a Role. -- Barrons.com

13 jan 2026, 17:54 UTC

Marktinformatie

UnitedHealth Reaffirms 2025 Guidance After Senate Report -- Market Talk

13 jan 2026, 17:50 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Global Equities Roundup: Market Talk

13 jan 2026, 17:50 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Netflix Will Be a Winner No Matter How Warner Saga Ends -- Market Talk

13 jan 2026, 17:49 UTC

Marktinformatie

Analysts Call For Potential Record Ethanol Output -- Market Talk

13 jan 2026, 17:38 UTC

Marktinformatie

Merck CEO Sees $5B Market for Cidara's Flu Antiviral -- Market Talk

13 jan 2026, 17:20 UTC

Marktinformatie

Financial Services Roundup: Market Talk

13 jan 2026, 17:20 UTC

Marktinformatie

Health Care Roundup: Market Talk

13 jan 2026, 17:20 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Basic Materials Roundup: Market Talk

13 jan 2026, 17:19 UTC

Marktinformatie

Credit Cards Present Opportunity, Potential Obstacle for JPMorgan -- Market Talk

13 jan 2026, 17:15 UTC

Marktinformatie

Merck CEO Sees Eventual Growth After Keytruda Exclusivity Expires -- Market Talk

Peer Vergelijking

Prijswijziging

MacroGenics Inc Prognose

Koersdoel

By TipRanks

67.6% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 3 USD  67.6%

Hoogste 4 USD

Laagste 2 USD

Gebaseerd op 4 Wall Street-analisten die 12-maands prijsdoelen bieden voor MacroGenics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Neutraal

4 ratings

1

Buy

3

Hold

0

Sell

Technische score

By Trading Central

1.47 / 1.64Steun & Weerstand

Korte Termijn

Neutral Evidence

Gemiddeld Termijn

Bullish Evidence

Lange Termijn

Bearish Evidence

Sentiment

By Acuity

320 / 361 Rangschikking in Gezondheidszorg

Nieuwssentiment

Bullish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over MacroGenics Inc

MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, a humanized monoclonal antibody targeting programmed death receptor-1; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.
help-icon Live chat